Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
25 adult subjects with moderate to severe plaque psoriasis will receive Ilumya 100mg subcutaneously at weeks 0, 4 and 16. At week 16, patients with remaining BSA ˃3% will be given HALOG ointment 0.1% to apply BID for 4 weeks. Patients who have ≤3% BSA at week 16 will remain on Ilumya monotherapy. Patients will continue to be evaluated at weeks 20 and 24.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
25
IL-23 injection
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, United States
RECRUITINGBody surface area
evaluation of body surface area percentage affected by psoriasis where 1 palm is equivalent to 1%
Time frame: 16 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.